^
Association details:
| Biomarker: | ER positive + PGR positive |
|---|---|
| Cancer: | HER2 Negative Breast Cancer |
| Drug: | tamoxifen (Estrogen receptor antagonist) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
6P - 25-year survival and benefit from tamoxifen therapy by the clinically used breast cancer markers in lymph node-negative and ER-positive/ HER2-negative breast cancer (ID 55)
Published date:
05/03/2021
Excerpt:
"...tamoxifen therapy benefit in patients with lymph node-negative and ER-positive/ HER2-negative breast cancer...A significant tamoxifen therapy benefit was suggested for patients with larger tumor size (T1c HR, 0.53; 95% CI, 0.32-0.89; T2 HR, 0.34; 95% CI, 0.16-0.73), lower tumor grade (Grade 1 HR, 0.24; 95% CI, 0.07-0.82; Grade 2 HR, 0.50; 95% CI, 0.31-0.80), and PR-positivity (HR=0.38, 95% CI, 0.24-0.62).
